Special Issue

The Pharmacology of Bisphosphonates: New Advances

Message from the Guest Editors

Bisphosphonates (BPs) are a class of compounds which are receiving growing interest in the pharmaceutical industry. Their therapeutic properties in bone-related disorders (e.g., osteoporosis, Paget's disease, or bone metastases) makes them the focus of several research studies as well as the main component of numerous pharmaceutical formulations. Thus, bisphosphonates are currently the target of intensive research, from basic pre-formulation studies to more advanced stages of clinical practice. Potential topics include, but are not limited to, the following: innovative synthetic approaches for the preparation of bioactive bisphosphonates, the bioactivity screening of bisphosphonic acids, repurposing and newly discovered biological effects of known compounds, as well as molecular modeling and structure-activity relationship studies. All types of research are encouraged, from in silico studies, through all varieties of in vitro and in vivo research to epidemiological, prospective, and retrospective clinical studies. I look forward to your valuable contributions.

Guest Editors

Dr. Ewa Chmielewska

Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, Wrocław, Poland

Prof. Dr. Paweł Kafarski

Chair of Chemistry, Department of Agriculture and Forestry, University of Warmia and Mazury, Olsztyn, Poland

Deadline for manuscript submissions

20 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202159

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

